Skip to content

Released May 8, 2025, before the open

10-Q filed May 8, 2025, 38 days after period end · 0001785530-25-000014

Q1 2025 · 10-Q
Revenue—
Net Income-$18.09MN/M vs Q1 2024N/M vs Q4 2024
EPS Diluted-$0.40N/M vs Q1 2024no prior Q4 2024 on file
Operating Income-$17,991,000N/M
Operating Cash Flow-$18,948,000N/M
Free Cash Flowderived-$18,948,000N/M

What the release said

The release

Same quarter

MetricQ1 2025Q1 2024Q1 2023Q1 2022
Net Income-$18.09M-$16.19M-$11.98M-$15.34M
EPS Diluted-$0.40-$0.39-$0.34-$0.56

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Werewolf Therapeutics, Inc. · CIK 1785530 · Engraved from SEC EDGAR